All companies
Visit website
KINEON
OperatingKineon, Inc.
Healthcare · Biotech · Founded 2021
Biotech company dedicated to changing the way we approach chronic pain through light therapy products
Post-money valuation ⓘ
$20.5M
As of Nov 2023 · from Kineon Common Stock 1 · pre-money + amount raised, not a traded price
Total raised
$459,677
Across 1 round since 2023
Latest share price
$1.00
Kineon Common Stock 1 offering price
Financials
FY2021–FY2025 · from SEC filings · hover any figure for its source$0
−$198K
2021
$1K
$22
2022
$2.9M
−$107K
2023
$10.3M
−$1.9M
2024
$6.8M
−$506K
2025
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2021
FY2022
FY2023
FY2024
FY2025
Income statement
Revenue
$0
$1,329
$2,887,269
$10,281,759
$6,785,478
Cost of goods sold
$0
$360
$549,768
$1,912,383
$1,279,184
Gross margin
—
73%
81%
81%
81%
Net income
-$197,792
$22
-$107,280
-$1,856,509
-$506,469
Taxes paid
$0
$0
$0
$0
$0
Balance sheet
Cash
$147,789
$66
$414,651
$488,585
$591,785
Accounts receivable
$0
$33
$0
$0
$48,547
Total assets
$157,078
$324
$905,089
$1,399,895
$1,153,932
Short-term debt
$345,915
$87
$12,360
$2,930,050
$3,090,556
Long-term debt
$0
$0
$105,595
$0
$0
Total liabilities
$345,915
$87
$117,955
$2,930,050
$3,090,556
Other
Headcount
—
17
17
17
17
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$20.5M
post-money
Kineon Common Stock 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $459.7K / $1.2MInvestors 274Post-money $20.5M
Reg CF annual-report compliance
Not requiredFewer than 300 holders of record
Filed 3 of 3 annual reports (FY2023–FY2025)
274 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0001987012Share price $1.00
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.